SPA
RARE icon

Sherbrooke Park Advisers’s Ultragenyx Pharmaceutical RARE Stock Holding History

Sherbrooke Park Advisers’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,882
Closed -$287K – 688
2025
Q2 		$287K Buy
+7,882
New +$284K 0.12% 315
2025
Q1 		– Sell
-10,387
Closed -$437K – 872
2024
Q4 		$437K Buy
+10,387
New +$515K 0.14% 262

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Sherbrooke Park Advisers's RARE Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of Ultragenyx Pharmaceutical (RARE) in Q3 2025, closing a stake of 7,882 shares — an estimated $287K sold.

Sherbrooke Park Advisers first reported a position in RARE in Q4 2024 and held it in 2 quarters. The position peaked at $437K in Q4 2024. 303 funds tracked by Wall St. Rank hold RARE as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining Ultragenyx Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 7,882 Ultragenyx Pharmaceutical shares in Q3 2025, an estimated $287K.
  • Sherbrooke Park Advisers first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and held it in 2 quarters.
  • Sherbrooke Park Advisers's Ultragenyx Pharmaceutical position peaked at $437K in Q4 2024.
  • 303 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.